[May 06, 2015] |
|
Quintiles Announces Pricing of $800 Million Senior Notes Offering
Quintiles Transnational Holdings Inc. (NYSE: Q) (the "Company" or
"Quintiles") announced today that Quintiles Transnational Corp.
("Quintiles Transnational"), its wholly owned subsidiary, has priced
$800 million principal amount of 4.875% senior unsecured notes due 2023
(the "Senior Notes") offered in a private placement that is exempt from
the registration requirements of the Securities Act of 1933, as amended
(the "Securities Act"). The Company intends to use the net proceeds of
the offering, together with proceeds from its previously announced
proposed senior secured credit facility, which is expected to increase
to a total of $1.95 billion, including $1.45 billion of term loans, to
refinance its existing credit facility, as well as for general corporate
purposes, including corporate transactions and equity repurchases. The
Senior Notes will be fully and unconditionally guaranteed on an
unsecured basis by Quintiles Transnational's domestic subsidiaries that
guarantee the senior secured credit facility.
The issuance of the Senior Notes is expected to occur on or about May
12, 2015, concurrently with the expected closing of the new senior
secured credit facility, subject to customary closing conditions. The
Senior Notes are being offered in the United States only to qualified
institutional buyers pursuant to Rule 144A under the Securities Act and
outside the United States to non-U.S. persons pursuant to Regulation S
under the Securities Act.
This announcement does not constitute an offer to sell or the
solicitation of an offer to buy the Senior Notes or any other
securities. The Senior Notes have not been, and will not be, registered
under the Securities Act, or any state securities laws, and may not be
offered or sold in the United States absent registration or an
applicable exemption from the registration requirements of the
Securities Ac and applicable state securities law.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
forward-looking statements reflect, among other things, our current
expectations regarding the offering of Senior Notes, the related
refinancing transactions and the use of proceeds therefrom, which are
subject to known and unknown risks, uncertainties and other factors that
may cause actual results to differ materially from those expressed or
implied by such forward-looking statements. Any statements contained
herein that are not statements of historical fact may be forward-looking
statements and should be evaluated as such. Without limiting the
foregoing, the words "anticipates," "believes," "estimates," "expects,"
"intends," "may," "plans," "projects," "should," "targets," "will" and
the negative thereof and similar words and expressions are intended to
identify forward-looking statements. Actual results may differ
materially from our expectations due to a number of factors, including
our ability to complete the proposed offering and refinancing on the
terms described or at all. For a further discussion of the risks
relating to our business, see the "Risk Factors" section in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2014, filed
with the SEC (News - Alert) on February 12, 2015, as such factors may be amended or
supplemented from time to time in our periodic filings with the SEC,
which are accessible on the SEC's website at www.sec.gov.
These factors should not be construed as exhaustive and should be read
in conjunction with the other cautionary statements that are included in
this release and in the Company's filings with the SEC. The Company
assumes no obligation to update any such forward-looking statement after
the date of this release, whether as a result of new information, future
developments or otherwise.
About Quintiles
Quintiles (NYSE: Q) is the world's largest provider of biopharmaceutical
development and commercial outsourcing services with a network of more
than 33,000 employees conducting business in approximately 100
countries. We have helped develop or commercialize all of the top-75
best-selling drugs on the market. Quintiles applies the breadth and
depth of our service offerings along with extensive therapeutic,
scientific and analytics expertise to help our customers navigate an
increasingly complex healthcare environment as they seek to improve
efficiency and effectiveness in the delivery of better healthcare
outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Click here
to subscribe to Mobile Alerts for Quintiles.
[ Back To Mobile World Congress's Homepage ]
|